Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2596 to 2610 of 8929 results

  1. Mezigdomide with dexamethasone and carfilzomib for treating relapsed or refractory multiple myeloma after at least 1 line of treatment [ID6513]

    Awaiting development Reference number: GID-TA11660 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Datopotamab deruxtecan for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer [ID6435]

    Awaiting development Reference number: GID-TA11535 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Pembrolizumab with chemotherapy for treating hormone receptor-positive HER2-negative locally recurrent inoperable or metastatic breast cancer [ID6285]

    Awaiting development Reference number: GID-TA11342 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Dupilumab for treating bullous pemphigoid [ID6479]

    Awaiting development Reference number: GID-TA11615 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Encorafenib with cetuximab and FOLFOX for untreated BRAF V600E mutation-positive metastatic colorectal cancer [ID6734]

    Awaiting development Reference number: GID-TA11961 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Apalutamide with gonadotrophin-releasing hormone agonist and radiotherapy for treating high-risk, localised or locally advanced prostate cancer [ID6215]

    Awaiting development Reference number: GID-TA11199 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. VER-01 for treating chronic low back pain [ID6638]

    Awaiting development Reference number: GID-TA11842 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Nipocalimab for treating generalised myasthenia gravis [ID6562]

    Awaiting development Reference number: GID-TA11492 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Rocatinlimab for treating moderate to severe atopic dermatitis in people 12 years and over [ID6565]

    Awaiting development Reference number: GID-TA11759 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Giredestrant with palbociclib for untreated oestrogen-receptor positive HER2-negative advanced breast cancer [ID5072]

    Awaiting development Reference number: GID-TA10960 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Iodine (131I)–apamistamab for treating relapsed or refractory acute myeloid leukaemia before an allogeneic haematopoietic stem cell transplant [ID6355]

    Awaiting development Reference number: GID-TA11425 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Lazertinib with amivantamab and platinum-based chemotherapy for EGFR mutation-positive metastatic non-small-cell lung cancer after a tyrosine kinase inhibitor [ID6305]

    Awaiting development Reference number: GID-TA11229 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Luspatercept for treating haemoglobin H disease [ID6714]

    Awaiting development Reference number: GID-TA11940 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Ruxolitinib for Prurigo Nodularis [ID6571]

    Awaiting development Reference number: GID-TA11760 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Pembrolizumab with chemoradiation, then with or without olaparib, for untreated unresectable locally advanced non-small-cell lung cancer [ID6399]

    Awaiting development Reference number: GID-TA11499 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development